The report provides forecasts and analyses for the global and regional chemotherapy-induced myelosuppression treatment markets. The study provides historical data from 2016 and revenue projections from 2019 to 2025. (USD Million).
The report details the market drivers and restraints for chemotherapy-induced myelosuppression treatments, as well as their impact on demand over the forecast period. In addition, the report examines opportunities within the global and regional markets for chemotherapy-induced myelosuppression treatment.
In order to provide readers with a thorough understanding of the chemotherapy-induced myelosuppression treatment market, we have included a competitive landscape and Porter’s Five Forces analysis. The study includes an analysis of market attractiveness, in which all segments are compared based on market size, growth rate, and overall attractiveness.
The report provides a market share analysis of key players in the chemotherapy-induced myelosuppression treatment market in order to provide a comprehensive overview of the industry. In addition, the report covers key strategic developments of the market, such as acquisitions & mergers, the launch of new indications, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major players involved in the global and regional chemotherapy-induced myelosuppression treatment market.
By segmenting the chemotherapy-induced myelosuppression treatment market based on indication, route of administration, drug class, distribution channel, and region, the study provides a crucial perspective on the market. All segments of the chemotherapy-induced myelosuppression treatment market have been analysed based on current and future trends, and the market from 2018 to 2025 has been forecasted.
Myelosuppression is the term used to describe the suppression of bone marrow. Myelosuppression results in decreased blood cell production due to decreased bone marrow activity. This may decrease all blood cell types, including red blood cells (RBCs), white blood cells (WBCs), and platelets. Pancytopenia is characterised by a reduction in all three types of blood cells. The most common side effect of chemotherapy is myelosuppression. Myelosuppression can range from mild to severe after chemotherapy. Extreme myelosuppression can be fatal and necessitates medical care. Symptoms of myelosuppression include fatigue, dizziness, shortness of breath, anaemia in the case of a reduction in red blood cells, and infection-related symptoms such as cough, chills, fever, etc. in the case of a reduction in white blood cells. Thrombocytopenia may result from a drop in platelet count.
The demand for chemotherapy-induced myelosuppression treatment is driven by the availability of advanced treatment options such as chemotherapy, surgery, and radiotherapy, the increasing preference for chemotherapy for cancer treatment, promising drug pipelines, the increasing prevalence of cancer across the globe, the growing awareness among patients, the rising healthcare expenditure and rising disposable income, and the introduction of cost-effective biosimilars.
(Get Special Discount) Buy Our Report: https://www.zionmarketresearch.com/buynow/su/chemotherapy-induced-myelosuppression-treatment-market
However, the loss of patent exclusivity and intense competition may impede the expansion of the market. Over the forecast period, the extensive drug pipeline and pharmaceutical companies’ emphasis on the development of safe and effective chemotherapy-induced myelosuppression treatment drugs will create new growth opportunities for market participants.
The chemotherapy-induced myelosuppression treatment market is segmented by indication into anaemia, neutropenia, and thrombocytopenia. The indication segment for neutropenia held the largest market share in 2018 and is anticipated to maintain its dominance throughout the forecast period. Neutropenia is the most common adverse effect of myelosuppression therapy. The severity and complications of neutropenia can be fatal and thus account for a significant proportion. The Thrombocytopenia segment will experience the greatest growth during the forecast period.
The market is segmented by drug class into thrombopoietic agents, erythropoietin-stimulating agents, iron supplements, growth factors, and others. In 2018, the growth factors drug class segment held the dominant market share. In contrast, the drug class segment of erythropoietin stimulating agents will experience the highest growth rate over the forecast period.
On the basis of route of administration, the market for chemotherapy-induced myelosuppression treatments is segmented into injectable and oral products. Injectable route of administration held the largest market share in 2018. This is because their therapeutic availability is greater than that of oral drugs.
The market for TNF inhibitors is segmented by distribution channel into retail pharmacies, hospital pharmacies, and online pharmacies. In 2018, retail pharmacies had the highest revenue share of all distribution channels. Online pharmacies are anticipated to experience rapid expansion in the coming years.
In 2018, North America dominated the global market for chemotherapy-induced myelosuppression treatments. Major growth drivers in this region include favorable reimbursement policies, robust commercial sales, a large patient pool, the presence of key players, and growing awareness.
In terms of revenue share, Europe was the second-largest regional market. Increasing cancer incidence, the availability of developed infrastructure, and heightened awareness are some of the factors driving market expansion in this region.
The Asia-Pacific region will be the fastest-growing market for myelosuppression treatments induced by chemotherapy. Important factors contributing to this region’s rapid growth include economic development, a rising geriatric population base and cancer prevalence, healthcare infrastructure improvement, rising healthcare spending and disposable income, and increasing awareness.
In contrast, Latin America will experience moderate growth over the next several years. The Middle East and Africa will experience slower growth in the coming years.
Teva Pharmaceutical Industries Ltd., Amgen Inc., Janssen Global Services, LLC, Pfizer Inc., Mylan NV, Mission Pharmacal Company, Myelo Therapeutics GmbH, Dova Pharmaceuticals, Partner Therapeutics, Inc., and Novartis AG are among the major players in the chemotherapy-induced myelosuppression treatment market
Read other Report: